Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 5/20 | 0.41 |
| ▸ | GSK3B | P49841 | 5/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 5/20 | 0.40 |
| ▸ | WNT1 | P04628 | 4/20 | 0.40 |
| ▸ | CASP6 | P55212 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA5A | P35218 | 1/20 | 0.36 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 2/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15542994 | 0.81 | GSK3B (0.44) | DPP4GSK3BDYRK1AWNT1MAPK1 | |
| SCHEMBL17091191 | 0.79 | KEAP1 (0.49) | CASP6MAPK1GRIN2B | |
| SCHEMBL17795637 | 0.78 | GSK3B (0.46) | GSK3BDYRK1AWNT1CA1CA2 | |
| SCHEMBL20868849 | 0.77 | KMO (0.44) | GSK3BDYRK1AWNT1MAPK1CA1 | |
| SCHEMBL17806601 | 0.75 | GSK3B (0.41) | DPP4GSK3BDYRK1AWNT1MAPK1 | |
| SCHEMBL15112015 | 0.75 | CHRM1 (0.55) | — | |
| SCHEMBL15729597 | 0.74 | HRH3 (0.45) | DPP4BRD4 | |
| SCHEMBL20868458 | 0.74 | GSK3B (0.39) | GSK3BDYRK1AWNT1 | |
| SCHEMBL23559594 | 0.72 | GSK3B (0.49) | GSK3BDYRK1AWNT1MAPK1SRC | |
| SCHEMBL17091082 | 0.72 | PRMT5 (0.50) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3144308-B1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2020-06-24 | — | — | EP | disclosed |
| US-10208046-B2 | Nitrogen-containing heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-02-19 | — | — | US | disclosed |
| EP-2921480-B1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2017-10-11 | — | — | EP | disclosed |
| EP-2921480-B1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2017-10-11 | — | — | EP | disclosed |
| US-9777005-B2 | Bicyclic heterocyclic compound containing a substituted pyrrole ring | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-10-03 | — | — | US | disclosed |
| US-9777005-B2 | Bicyclic heterocyclic compound containing a substituted pyrrole ring | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-10-03 | — | — | US | disclosed |
| US-9777005-B2 | Bicyclic heterocyclic compound containing a substituted pyrrole ring | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-10-03 | — | — | US | disclosed |
| US-9732086-B2 | — | — | 2017-08-15 | — | — | US | disclosed |
| US-9732086-B2 | — | — | 2017-08-15 | — | — | US | disclosed |
| US-9732086-B2 | — | — | 2017-08-15 | — | — | US | disclosed |
| US-20170081332-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-03-23 | — | — | US | disclosed |
| EP-3144308-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-03-22 | — | — | EP | disclosed |
| US-20150307497-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-10-29 | — | — | US | disclosed |
| US-20150307497-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-10-29 | — | — | US | disclosed |
| US-20150307497-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-10-29 | — | — | US | disclosed |
| EP-2921480-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2015-09-23 | — | — | EP | disclosed |
| EP-2921480-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2015-09-23 | — | — | EP | disclosed |
| WO-2014077401-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | 武田薬品工業株式会社 (JP) | 2014-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10208046-B2 | Nitrogen-containing heterocyclic compound | CHRM1, CHRM5, CHRM2 | DPP4 3435/4885GSK3B 1657/4885DYRK1A 1815/4885 |
| US-20150307497-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | CHRM1, CHRM2, CHRM4 | DPP4 4542/4885GSK3B 1755/4885DYRK1A 2893/4885 |
| US-20170081332-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | CHRM1, CHRM5, CHRM2 | DPP4 3435/4885GSK3B 1657/4885DYRK1A 1815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.